Lipid nanoparticle compositions and uses thereof

A method for delivering lipid nanoparticles (LNPs) to the lungs of a subject having a CFTR genotype comprising a W1282X mutation, a R553X mutation, or both, wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject,

• wherein the liquid pharmaceutical composition comprises lipid nanoparticles (LNPs) having a diameter between 20 nm and 600 nm,
• wherein the LNPs comprise:
• (a) an ionizable lipid,
• (b) a phospholipid,
• (c) a PEG-lipid,
• (d) a sterol, and
• (e) an mRNA encoding a Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein, and
• wherein the aerosolized particles deliver the mRNA to the lungs in an amount effective to induce or increase expression and/or function of a protein encoded by the mRNA in lung cells.